Lipids and lipid compositions for the delivery of active agents

Patent metadata

Field	Value
Publication number	US-10124065-B2
Application number	US-201414779939-A
Country	US
Kind code	B2
Filing date	Mar 6, 2014
Priority date	Mar 8, 2013
Publication date	Nov 13, 2018
Grant date	Nov 13, 2018

Abstract

This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 -R 4 , L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

First claim

What is claimed is:

1. A method for the treatment of a disease or condition comprising administering to a patient in need thereof a therapeutically effective amount of a lipid composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein:

L is C 1-6 alkylene, *—C 1-4 alkylene-L2-, or *—C 1-4 alkylene-L2-C 1-4 alkylene-, wherein the * denotes attachment of the moiety to the NR 1 R 2 group;
L2, attached in either direction, is —C(O)O—;
R 1 and R 2 are each independently optionally substituted C 1-6 alkyl, wherein said C 1-6 alkyl is optionally substituted with one or two substituents each independently selected from the group consisting of: OH, C 1-3 alkoxyl, COOH, and COO—C 1-4 alkyl,
R 3 and R 4 are each independently —Z 1 —R b —Z 2 —R a , wherein Z 1 , attached in either direction, is each independently —O— or —C(O)O—;
Z 2 , attached in either direction, is —C(O)O—;
R a is C 2-22 alkyl, C 2-22 alkenyl, or C 2-22 alkynyl;
each R b is independently C 1-20 alkylene, C 2-20 alkenylene, or C 2-20 alkynylene;
provided that —Z 1 —R b —Z 2 —R a has at least 12 carbon atoms and no more than 30 carbon atoms;
X is CR 6 ; and
R 6 is H, halo, C 1-6 alkyl, or R 4 ;

and
an mRNA agent.

2. The method of claim 1 , comprising administering a lipid composition comprising:
a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein:

L is C 1-6 alkylene, *—C 1-4 alkylene-L2-, or *—C 1-4 alkylene-L2-C 1-4 alkylene-, wherein in the * denotes attachment of the moiety to the NR 1 R 2 group;

L2, attached in either direction, is —C(O)O—;
R 1 and R 2 are each independently optionally substituted C 1-6 alkyl, ; wherein said C 1-6 alkyl is optionally substituted with one or two substituents each independently selected from the group consisting of: OH, C 1-3 alkoxy, COOH, and COO—C 1-4 alkyl,
R 3 and R 4 are each independently —Z 1 —R b —Z 2 —R a , wherein Z 1 , attached in either direction, is each independently —O— or —C(O)O—;

Z 2 , attached in either direction, is —C(O)O—;
R a is C 2-22 alkyl, C 2-22 alkenyl, or C 2-22 alkynyl;
each R b is independently C 1-20 alkylene, C 2-20 alkenylene, or C 2-20 alkynylene;
provided that —Z 1 —R b —Z 2 —R a has at least 12 carbon atoms and no more than 30 carbon atoms;
X is CR 6 ; and
R 6 is H, halo, C 1-6 alkyl, or R 4 ;
an mRNA;

and
a pharmaceutically acceptable carrier or excipient.

3. A method for the treatment of a disease or condition comprising administering to a patient in need thereof a therapeutically effective amount of a lipid composition comprising:
a compound of formula:

(9Z, 9′Z, 12Z, 12′Z)-((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl)bis(octadeca-9, 12-dienoate),
or a pharmaceutically acceptable salt thereof;

and
an mRNA agent.

4. The method of claim 3 , comprising administering a lipid composition comprising:
a compound of formula:

(9Z, 9′Z, 12Z, 12′Z)-((5-((dimethylamino)methyl)-1, 3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9, 12-dienoate)
or a pharmaceutically acceptable salt thereof;

an mRNA;
and
a pharmaceutically acceptable carrier or excipient.

5. A method for the treatment of a disease or condition comprising administering to a patient in need thereof a therapeutically effective amount of a lipid composition comprising:
a compound of formula:

((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(octane-8,1-diyl)bis(decanoate),
or a pharmaceutically acceptable salt thereof;

and
an mRNA agent.

6. The method of claim 5 , comprising administering a lipid composition comprising:
a compound of formula:

((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(octane-8,1-diyl)bis(decanoate),
or a pharmaceutically acceptable salt thereof;

an mRNA;
and
a pharmaceutically acceptable carrier or excipient.

7. The method of claim 1 , wherein the composition comprises one or more of a helper lipid, a neutral lipid, and a stealth lipid.

8. The method of claim 7 , wherein the helper lipid is cholesterol, the neutral lipid is DSPC, and the stealth lipid is PEG-DMG, S010, or S011.

9. The method of claim 3 , wherein the composition comprises one or more of a helper lipid, a neutral lipid, and a stealth lipid.

10. The method of claim 9 , wherein the helper lipid is cholesterol, the neutral lipid is DSPC, and the stealth lipid is PEG-DMG, S010, or S011.

11. The method of claim 5 , wherein the composition comprises one or more of a helper lipid, a neutral lipid, and a stealth lipid.

12. The method of claim 11 , wherein the helper lipid is cholesterol, the neutral lipid is DSPC, and the stealth lipid is PEG-DMG, S010, or S011.

13. The method of claim 1 , wherein the composition is in a form of a lipid nanoparticle.

14. The method of claim 3 , wherein the composition is in a form of a lipid nanoparticle.

15. The method of claim 5 , wherein the composition is in a form of a lipid nanoparticle.

16. The method of claim 8 , wherein the stealth lipid is PEG-DMG.

17. The method of claim 10 , wherein the stealth lipid is PEG-DMG.

18. The method of claim 12 , wherein the stealth lipid is PEG-DMG.

19. The method of claim 8 , wherein the lipid composition has a molar ratio of about 40/about 38/about 10/about 2 of the compound of formula (I)/cholesterol/DSPC/PEG-DMG, S010, or S011, respectively.

20. The method of claim 10 , wherein the lipid composition has a molar ratio of about 40/about 38/about 10/about 2 of the compound of (9Z, 9′Z, 12Z, 12′Z)-((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9, 12-dienoate)/cholesterol/DSPC/PEG-DMG, S010, or S011, respectively.

21. The method of claim 12 , wherein the lipid composition has a molar ratio of about 40/about 38/about 10/about 2 of a compound of ((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(octane-8,1-diyl)bis(decanoate)/cholesterol/DSPC/PEG-DMG, S010, or S011, respectively.

Assignees

• Novartis Ag

Inventors

• Baryza Jeremy Lee
• Beckwith Rohan Eric John
• Bowman Keith
• Byers Crystal
• Fazal Tanzina
• Gamber Gabriel Grant
• Lee Cameron Chuck-Munn
• Tichkule Ritesh Bhanudasji
• Vargeese Chandra
• Wang Shuangxi
• West Laura
• Zabawa Thomas
• Zhao Junping

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P33/00

  Antiparasitic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P9/12

  Antihypertensives · CPC title